Related Experiment Video
Updated: Sep 1, 2025
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.7K
Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Tomohiro Fujiwara1, Eiji Nakata2, Toshiyuki Kunisada2
1Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, Japan. tomomedvn@okayama-u.ac.jp.
BMC Cancer
|August 15, 2022
Summary
Alveolar soft part sarcoma (ASPS) is a rare cancer that often spreads to the lungs and brain. Targeted therapy like pazopanib shows promise for improving survival in metastatic ASPS patients.
Area of Science:
- Oncology
- Sarcoma Research
- Medical Therapeutics
Background:
- Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma subtype.
- ASPS is known to be resistant to conventional chemotherapy.
Purpose of the Study:
- To characterize ASPS and its clinical course.
- To investigate improvements in oncological outcomes for ASPS over the past decade.
Main Methods:
- Retrospective analysis of 120 newly diagnosed ASPS patients from 2006-2017.
- Data sourced from the Bone and Soft-Tissue Tumor Registry in Japan.
Main Results:
- Metastasis at presentation was the primary adverse prognostic factor for disease-specific survival (DSS).
- Patients treated with pazopanib showed prolonged survival compared to those receiving doxorubicin-based chemotherapy.
- A trend towards improved DSS for metastatic ASPS was observed after pazopanib's approval in 2012.
Conclusions:
- ASPS exhibits frequent lung and brain metastasis with an indolent clinical course.
- Targeted therapy introduction shows a trend toward prolonged survival.
- Further development of novel therapies is encouraged for this resistant sarcoma.
Related Concept Videos
01:21Cancer Survival Analysis
433
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
433
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
01:20Actuarial Approach
121
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
121